In most countries, pemphigus is one of those rare, potentially life-threatening skin and mucosal diseases that is referred to specialist centers for treatment. Because it is rare, there is a paucity of randomized clinical trials (RCTs) to inform dermatologists of the most effective and safe treatments.1 For rare diseases, meta-analysis, a statistical tool that allows pooling together the results of smaller, similar clinical trials, can be just as valuable as larger clinical trials, but in order to pool the data the studies need to use the same outcome measures for disease assessment.
Murrell DF, Amagai M, Werth VP. Scoring Systems for Blistering Diseases in Practice: Why Bother, and Which One Should You Use? JAMA Dermatol. 2014;150(3):245–247. doi:10.1001/jamadermatol.2013.8179
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.